C12Y 207/11022
Cyclin-dependent kinase
Official title: Cyclin-dependent kinase (2.7.11.22)
C12Y207/11022 (Cyclin-dependent kinase) appears on 46 US grants and 104 published applications in this corpus.
Search patents in C12Y- Granted patents
- 46
- Published applications
- 104
- Assignees
- 68
- Inventors
- 189
- Latest grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 3 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 2 | 2 |
| 2003 | 1 | 4 |
| 2004 | 0 | 10 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 1 |
| 2010 | 0 | 4 |
| 2011 | 0 | 2 |
| 2012 | 0 | 3 |
| 2013 | 2 | 3 |
| 2014 | 1 | 2 |
| 2015 | 1 | 4 |
| 2016 | 2 | 3 |
| 2017 | 3 | 4 |
| 2018 | 4 | 7 |
| 2019 | 3 | 9 |
| 2020 | 5 | 5 |
| 2021 | 6 | 5 |
| 2022 | 1 | 8 |
| 2023 | 3 | 10 |
| 2024 | 1 | 3 |
| 2025 | 1 | 6 |
| 2026 | 3 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for inducing cell division of postmitotic cells23 Jun 2026US 12,661,384 B2The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
- Gene therapy for treating CDKL5 deficiency disorder9 Jun 2026US 12,649,006 B2Ultragenyx Pharmaceutical Inc.
- Cyclic peptide useful in the treatment of cancer10 Mar 2026US 12,570,697 B2Syntherix Limited
- Compositions and methods involving engineered P271 Apr 2025US 12,264,339 B2The Regents of the University of California
- Methods of sensitizing cancer to immunotherapy30 Jan 2024US 11,884,730 B2Case Western Reserve University
- Formulations comprising recombinant aav and methods of administering the same8 Oct 2026US 2026/0306663 A1Ultragenyx Pharmaceutical Inc.
- Compositions and methods for the treatment of disorders related to cdkl5 deficiency1 Oct 2026US 2026/0295084 A1Voyager Therapeutics, Inc.
- RNA-Based Compositions and Methods for Treating Breast Cancer24 Sep 2026US 2026/0286354 A1Avicenna Biotech Research, LLC
- Compounds, compositions, and methods of use thereof13 Aug 2026US 2026/0234112 A1Type6 Therapeutics, Inc.
- Treatment for cdkl5 deficiency disorder6 Aug 2026US 2026/0224670 A1The Francis Crick Institute Limited
Most cited
By later US patents
- Inhibition of proliferation of vascular smooth muscle cell31US 5,821,234 AThe Board of Trustees of the Leland Stanford Junior University · 1998
- Inhibition of proliferation of vascular smooth muscle cell11US 5,869,462 AThe Board of Trustees of the Leland Stanford Junior University · 1999
- Double-stranded oligonucleotides11US 9,592,250 B2Life Technologies Corporation · 2017
- Nucleotide monomers containing 8-azapurin bases or a derivative thereof, their preparation and their use in making modified olignonucleotides9US 5,789,562 AHoechst Aktiengesellschaft · 1998
- Double-stranded oligonucleotides7US 8,815,821 B2Life Technologies Corporation · 2014